Elicio Therapeutics, Inc. (ELTX)
Company Description
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases.
The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers.
It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers.
The company is headquartered in Boston, Massachusetts.
Country | United States |
Founded | 2011 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 23 |
CEO | Robert T. Connelly |
Contact Details
Address: One Kendall Square, Building 1400 West, Suite 14303 Cambridge, Massachusetts 02139 United States | |
Phone | 857-209-0056 |
Website | elicio.com |
Stock Details
Ticker Symbol | ELTX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001555192 |
ISIN Number | US28657F1030 |
Employer ID | 45-2966790 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Robert T. Connelly | Chief Executive Officer, President and Director |
Dr. Christopher M. Haqq M.D., Ph.D. | Executive Vice President, Head of Research and Development and Chief Medical Officer |
Prof. Darrell J. Irvine Ph.D. | Co-Founder, Consultant, Board Observer and Chairman of Scientific Advisory Board |
Brian Piekos | Chief Financial Officer |
Michael DiVecchia | Senior Vice President of Operations and Human Resources |
Dr. Peter DeMuth Ph.D. | Chief Scientific Officer |
Megan C. Filoon | General Counsel, Secretary and Compliance Officer |
Esther Welkowsky | Senior Vice President of Clinical Development |
Joy Seymour | Vice President and Head of Regulatory Affairs |
Dr. Thian Kheoh Ph.D. | Senior Vice President of Biometrics |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 2, 2022 | D/A | Filing |
Sep 13, 2022 | RW | Filing |
May 27, 2022 | D | Notice of Exempt Offering of Securities |
Nov 18, 2021 | D/A | Filing |
Nov 12, 2021 | D/A | Filing |
Oct 19, 2021 | D | Notice of Exempt Offering of Securities |
Jul 13, 2021 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Jun 29, 2021 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Jun 28, 2021 | S-1 | General form for registration of securities under the Securities Act of 1933 |
Jun 9, 2021 | DRS/A | [Amend] [Cover] Draft Registration Statement |